Flc Capital Advisors Amgen Inc Transaction History

Flc Capital Advisors

  • $430 Million
  • Q3 2024

A detailed history of Flc Capital Advisors transactions in Amgen Inc stock. As of the latest transaction made, Flc Capital Advisors holds 2,086 shares of AMGN stock, worth $548,993. This represents 0.16% of its overall portfolio holdings.

Number of Shares
2,086
Previous 2,086 -0.0%
Holding current value
$548,993
Previous $651,000 3.23%
% of portfolio
0.16%
Previous 0.16%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 15, 2024
BUY
$262.75 - $319.31 $13,137 - $15,965
50 Added 2.46%
2,086 $651,000
Q3 2023

Jan 18, 2024
SELL
$218.65 - $271.46 $38,701 - $48,048
-177 Reduced 8.0%
2,036 $547,000
Q4 2022

Jan 27, 2023
SELL
$229.03 - $291.01 $58,631 - $74,498
-256 Reduced 10.37%
2,213 $581,000
Q3 2022

Oct 14, 2022
BUY
$224.46 - $253.15 $1,346 - $1,518
6 Added 0.24%
2,469 $557,000
Q3 2021

Oct 13, 2021
SELL
$212.27 - $248.7 $11,674 - $13,678
-55 Reduced 2.18%
2,463 $524,000
Q2 2020

Jul 10, 2020
SELL
$197.81 - $242.74 $6,329 - $7,767
-32 Reduced 1.25%
2,518 $645,000
Q1 2020

Apr 09, 2020
SELL
$182.24 - $241.7 $35,354 - $46,889
-194 Reduced 7.07%
2,550 $533,000
Q3 2019

Oct 29, 2019
SELL
$174.11 - $208.62 $22,460 - $26,911
-129 Reduced 4.49%
2,744 $531,000
Q2 2019

Aug 05, 2019
BUY
$166.7 - $195.41 $48,009 - $56,278
288 Added 11.14%
2,873 $524,000
Q1 2019

May 13, 2019
BUY
$180.87 - $203.88 $133,301 - $150,259
737 Added 39.88%
2,585 $491,000
Q4 2018

Feb 11, 2019
BUY
$178.4 - $208.25 $329,683 - $384,846
1,848 New
1,848 $360,000

Others Institutions Holding AMGN

# of Institutions
3,125
Shares Held
409M
Call Options Held
7.56M
Put Options Held
7.2M
View Full List

About AMGEN INC

AMGN Quotes by TradingView
  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $141B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Flc Capital Advisors Portfolio

Follow Flc Capital Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Flc Capital Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Flc Capital Advisors with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email